HLD-0117: A treatment cycle consists of 28 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)
Study summary
Assessment of the safety and efficacy of HLD-0117 as monotherapy in patients with estrogen receptor positive (ER+) metastatic breast cancer (MBC) or locally advanced breast cancer that have progressed on prior systemic therapies.
Eligibility
Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Female (assigned at birth), ≥18 years old, and able to provide informed consent
* Histologically confirmed metastatic or locally advanced breast cancer
* Postmenopausal status defined by surgical or natural menopause, or ovarian suppression with a GnRH agonist
* Prior treatment including at least one endocrine therapy in the metastatic setting, at least one CDK4/6 inhibitor (in the adjuvant and/or metastatic setting), and no more than two prior cytotoxic regimens in the metastatic setting
* Radiologic disease progression on the most recent therapy
* Measurable disease per RECIST v1.1
* Willingness to provide baseline and on-treatment tumor biopsies, unless not feasible or medically appropriate
* ER-positive and HER2-negative status documented within 2 years
* ECOG performance status 0-1 and life expectancy of at least 3 months
* Adequate organ function Recovery from prior therapy-related toxicities to Grade ≤1 (except alopecia; neuropathy and endocrinopathies ≤Grade 2)
* Ability to swallow oral medication and comply with study procedures
* Stable dose (≥30 days) of bisphosphonates or denosumab, if applicable
Exclusion Criteria:
* Inflammatory breast cancer or known brain metastases
* Recent major bleeding or uncontrolled bleeding disorder
* Ongoing corticosteroid use \>10 mg/day (prednisone equivalent)
* Recent anticancer or investigational therapy within 14 days (28 days for fulvestrant)
* Untreated or unstable spinal cord compression
* Significant cardiovascular disease within 6 months or ongoing uncontrolled cardiac conditions
* Active or uncontrolled infection (controlled HIV or treated hepatitis C allowed)
* Uncontrolled renal, pancreatic, or liver disease (excluding stable conditions such as Gilbert's syndrome or liver metastases)
* Another malignancy requiring treatment within 2 years (except low-risk, curatively treated cancers)
* Major surgery within 28 days
* Any condition that may interfere with safety or study compliance
* Pregnancy or breastfeeding
Primary outcome measure(s)
Dose Limiting Toxicities (DLTs) — 28 days Frequency of dose-limiting toxicities (DLTs)
AEs, ECGs, Labs and Clinical Changes — 28 days Frequency and severity of adverse events (AEs) and abnormal electrocardiogram (ECG), laboratory and clinical changes from baseline
Trial sites (6)
Facility
City
Region
Status
Yale University School Of Medicine
New Haven
Connecticut
Recruiting
Florida Cancer Specialists
Sarasota
Florida
Recruiting
Massachusetts General Hospital
Boston
Massachusetts
Recruiting
SCRI Oncology Partners
Nashville
Tennessee
Recruiting
South Texas Accelerated Research Therapeutics, LLC (START)
San Antonio
Texas
Recruiting
Next Virginia
Fairfax
Virginia
Recruiting
More Janssen Research & Development, LLC trials in the USA
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.